At the 58th American Society of Hematology (ASH) Annual Meeting & Exposition, John Gribben, MD, DSc, and Stephan Stilgenbauer, MD, discuss drug combination approaches in chronic lymphocytic leukemia (CLL) therapy. Targeting multiple molecules or pathways may have the potential to improve treatment response.
Get great new content delivered to your inboxSign up
By choosing to continue, you are confirming that you are a healthcare professional
Please enter your details if you would like to receive the latest Hemonc news and updates